This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact journals.permissions@oup.com

Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine © The Author 2014. Advance Access publication 5 November 2014 Health Policy and Planning 2015;**30**:1152–1161 doi:10.1093/heapol/czu120

Achieving universal health coverage goals in Thailand: the vital role of strategic purchasing

Viroj Tangcharoensathien,¹* Supon Limwattananon,² Walaiporn Patcharanarumol,³ Jadej Thammatacharee,⁴ Pongpisut Jongudomsuk⁴ and Supakit Sirilak⁵

¹International Health Policy Program (IHPP), Ministry of Public Health, Thanon Tiwanon, Nonthaburi 11000 Thailand, ²Faculty of Pharmaceutical Sciences, Khon Kaen University, 123 Mitraparp Highway, Khon Kaen 40002 Thailand, ³International Health Policy Program (IHPP), Ministry of Public Health, Thanon Tiwanon, Nonthaburi 11000 Thailand, ⁴National Health Security Office, Government Complex, Changwattana, Bangkok 10210 Thailand and ⁵Health Technical Office, Ministry of Public Health, Thanon Tiwanon, Nonthaburi 11000 Thailand

*Corresponding author. International Health Policy Program (IHPP), Ministry of Public Health, Nonthaburi 11000, Thailand. E-mail: viroj@ihpp.thaigov.net

Accepted 30 September 2014

Strategic purchasing is one of the key policy instruments to achieve the universal health coverage (UHC) goals of improved and equitable access and financial risk protection. Given favourable outcomes of Universal Coverage Scheme (UCS), this study synthesized strategic purchasing experiences in the National Health Security Office (NHSO) responsible for the UCS in contributing to achieving UHC goals. The UCS applied the purchaser-provider split concept where NHSO, as a purchaser, is in a good position to enforce accountability by public and private providers to the UCS beneficiaries, through active purchasing. A comprehensive benefit package resulted in high level of financial risk protection as reflected by low incidence of catastrophic health spending and impoverished households. The NHSO contracted the District Health System (DHS) network, to provide outpatient, health promotion and disease prevention services to the whole district population, based on an annual age-adjusted capitation payment. In most cases, the DHS was the only provider in a district without competitors. Geographical monopoly hampered the NHSO to introduce a competitive contractual agreement, but a durable, mutually dependent relationship based on trust was gradually evolved, while accreditation is an important channel for quality improvement. Strategic purchasing services from DHS achieved a propoor utilization due to geographical proximity, where travel time and costs were minimal. Inpatient services paid by Diagnostic Related Group within a global budget ceiling, which is estimated based on unit costs, admission rates and admission profiles, contained cost effectively. To prevent potential underprovisions of the services, some high cost interventions were unbundled from closed end payment and paid on an agreed fee schedule. Executing monopsonistic purchasing power by NHSO brought down price of services given assured quality. Cost saving resulted in more patients served within a finite annual budget.

Keywords Universal health coverage, universal coverage scheme, Thailand, purchasing functions

KEY MESSAGES

- Strategic purchasing function, if managed well by insurance agencies, contributes to achieving universal health coverage (UHC) goals of equitable access and financial risk protection. Availabilities of functioning primary healthcare services and proper referral backup to secondary and tertiary care are vital.
- Fee for service, when payment related to number of items of services provided, stimulated excessive provision of services, inefficient use of resources and cost escalation. In contrast, closed-end payment such as capitation and diagnostic related group send strong signal to providers to use generic medicines, appropriate use of technologies and self-cost containment resulting in efficiency. National Drug Regulatory Authority is responsible to ensure quality of generic medicines in the market.
- To prevent under-provisions of services, some high cost interventions can be singled out from closed end payment, and pay on an agreed fee schedule. Institutional capacity needs to be strengthened and sustained in managing strategic purchasing.
- There are great opportunities for insurance agencies to execute monopsonistic purchasing power, namely a single buyer from multiple sellers of healthcare services to gain the best possible price given assured quality of goods and services.

Introduction

In 2001, prior to the achievement of universal health coverage (UHC), \sim 30% of the Thai population were uninsured despite a gradual extension of coverage to various population groups (Tangcharoensathien *et al.* 2009). In 2002, >98% of population were covered by one of the three financial risk protection schemes: Civil Servant Medical Benefit Scheme (CSMBS) for public employees and dependants, Social Health Insurance (SHI) for private employees and Universal Coverage Scheme (UCS) for the remaining population who were not covered by the former two Schemes. Though benefit package was quite similar across the three schemes, the CSMBS pays outpatient (OP) services based on fee for service resulting in a high level of per capita expenditure, US\$ 366 in 2011, 3.8 times higher than the UCS expenditure, Table 1.

UCS was selected for detail investigation as it covers the largest population. This article reviewed purchasing experiences for which the National Health Security Office (NHSO) who manages UCS had gradually developed and discussed how these purchasing functions contributed to the achievement of improved and equitable use of health service and financial risk protection to its members.

Document reviews were conducted; main sources were NHSO archives mostly grey documents related to UCS operations, e.g. minutes of the meetings of NHSO Governing Board and its related sub-committees such as Benefit, Finance and Budget, purchased price of goods and services after negotiation and its annual report. Published literatures related to UCS outcome were retrieved.

Findings

UCS performance

Improved and equitable access

The UCS members were entitled to free services at their registered District Health System (DHS) network; an increased utilization was observed both OP and inpatient (IP) services (Tangcharoensathien *et al.* 2013). Not only use rate increased, but also pro-poor utilization especially at health centres, district

hospitals for OP and IP was observed. The DHS network in each district, consisting of 10–15 sub-district health centres and a district hospital—so called the 'close to client' provider was contracted based on capitation to provide OP services to the catchment population (Prakongsai 2008).

Using a difference-in-difference method (Limwattananon et al. 2013), a causal impact of UCS resulted in a reduced probability that a reported ill person did not have formal treatment and an increased probability of the use of public OP service, mostly provided by district hospitals and of IP in a public hospital. These effects are largest for the elderly. An increase in the OP utilization was greatest among the poor and rural residents, whereas there is a significant impact on IP care only among urban population. There was no evidence of crowding out of private formal care, reflecting that UCS reform made care more accessible to individuals previously financially deterred from utilization. Removal of user fees at public care appeared not to have induced users of private facilities to switch to the public sector, which may indicate convenience gaps between public and private providers.

It is noted that primary care services in Thailand are usually delivered by paramedics in health centres or general doctors in OP departments of district or provincial hospitals for which medicines were also dispensed. There are no primary care systems where family doctors or general practitioners diagnose and prescribe and patients receive medicines from another dispensary or pharmacies. Statistics showed increased OP utilization at district heath systems which beneficiaries can effectively use with low travel cost.

Prior to UHC in 2002, the government health spending, as measured by benefit incidence, was in favour of the poor (O'Donnell *et al.* 2007); a similar pro-poor trend continued in subsequent years, in particular at district and provincial hospitals. Subsidy for the OP service used by the poorest quintile of UCS members was 27–30% compared with their respective share of members, 23–24% of total UCS population, whereas the richest quintiles gained the benefit of 7–11% of the total subsidies, less than the population share, 12–13% of total UCS members (Limwattananon *et al.* 2012), see Figure 1.




Figure 1 Distribution of OP and IP government subsidies by wealth quintile when compared with the UCS beneficiary distribution, 2003–2009

Financial risk protection

The predominant general tax financed UCS and CSMBS had led to an overall progressive financial incidence, where the rich contributed to health financing in a higher proportion of their income than the poor. The Concentration Indexes of financial contributions (ranges from -1 to +1, the more positive, the more progressive, where the rich pay higher proportion of their income to finance health) were consistently progressive (Prakongsai *et al.* 2009). See Table 2.

A study by Limwattananon *et al.* (2013) demonstrated that mean household medical expenditures was reduced by onethird, whereas spending at the very top of the distribution of medical expenditures (i.e. the 95th conditional quantile) was reduced by one-half.

Financial risk protection had greatly improved; there was a minimal incidence of catastrophic health expenditure, as measured by household out-of-pocket payment for health exceeding 10% of total household consumption expenditure (Evans *et al.* 2012); see Figure 2. The incidence of medical impoverishment, as measured by an additional number of non-poor households falling under the national poverty lines as a result of health payments was low and decreasing (Limwattananon *et al.* 2007).

UCS strategic purchasing functions

Content analysis of the document reviews resulted in key strategies in six issues of the purchasing functions.

Design of benefit packages

For services to be included in benefit packages, UCS applies negative list concept—all diseases and services were covered except a few such as aesthetic surgeries and proven ineffective interventions. Maximum ceiling of financial coverage for each treatment was not applicable. Later in 2008 when Thailand had developed more capacity on health technology assessment (HTA) (Tangcharoensathien and Kamolratanakul 2008; Jongudomsuk *et al.* 2012), inclusion of new interventions into the UCS benefit package was guided by evidence through stringent economic evaluation, budget impact assessment and ethical concerns especially when there was limited supply-side capacities to offer such new services equitably.

Health Intervention and Technology Assessment Programme (HITAP) established in 2007 (HITAP 2013) as a research organization, contributed studies with major policy impacts, such as the economic evaluation of cervical cancer screening and human papilloma virus vaccines (Yothasamut *et al.* 2010). One Gross National Income per capita for a quality-adjusted life year was applied as a benchmark for public investment in health (Tantivess *et al.* 2009).

Renal replacement therapy (RRT) was initially excluded from the UCS benefit package due to its high cost (Kasemsup et al. 2006). UCS members faced catastrophic spending, whereas CSMBS and SHI fully covered (Prakongsai et al. 2007). RRT was heavily analysed over several years, including demand estimates (Kasemsup et al. 2006), cost-effectiveness analysis (Teerawattananon et al. 2007), policy analysis (Prakongsai et al. 2006) and public opinion surveys (Tangcharoensathien et al. 2006). Clearly, RRT was not cost-effective and contributed to long-term fiscal burden (Tangcharoensathien et al. 2005), especially given an increasing prevalence of diabetes and hypertension. Despite cost ineffective, the government in 2006 decided to include RRT into the UCS benefit package, to prevent catastrophic spending and ensure equity across all Schemes financed by public resources (Tangcharoensathien et al. 2013). Peritoneal dialysis first policy was adopted in view

	UCS	SHI	CSMBS			
1. Legal status	National Health Security Act	Social Security Act	Royal Decree			
2. Established since	2002	1990	1980			
3. Responsible agency	NHSO	MOL, Social Security Office	MOF, Comptroller General Dept.			
4. Population coverage, % of total	People who are not covered by SHI and CSMBS, 75%	Private sector employees, no dependents, 15%	Government employee, pen- sioners, dependants, 9%			
5. Financing sources	General tax, through annual budget bill	Tripartite, 4.5% payroll, 1.5% each	General tax, through annual budget bill			
6. Expenditure per capita, 2011	2900 Baht (US\$ 97)	~2134 Baht (US\$ 71)	~11000 Baht (US\$ 366)			
7. Benefit package	Comprehensive, small exclu- sion list	Comprehensive, small exclusion list	Comprehensive, no explicit ex- clusion list, private bed covered			
8. Prevention/promotion	Mar	Managed by NHSO for whole population since 2002				
9. Providers	Mostly public network, typ- ical DHS (DH + HCs)	Competing public, private hos- pitals > 100 beds (60% private)	Public provider only, selected disease (2011)			
10. Registration with provider	Required, limited choice to domicile district for OP	Required, annual choices if needed	Not required			
11. Choices of provider when ill	Limited to registered con- tractor network, plus referral	Limited to registered contractor hospital and its network	Free choice to any public, no referral required			
12. Choices of providers for accident and emergency services	Free choice	Free choice	Free choice			
13. Gate keeping function	Yes for OP	Yes for OP and IP	No			
14. Provider payment methods	OP: Capitation (age adjusted)	Capitation inclusive for OP and IP	OP: Fee-for-service			
	IP: DRG with global budget	DRG for IP DRG $RW > 2$	IP: DRG multiple baserates, 2007			
15. Additional payment	Fe	ee schedules for selected conditions or se	ervices			
16. Copayment	No, full pay when bypassing registered providers with- out proper referral	No, full pay outside contractor	Full pay in private			

Table 1 Key characteristics across three public health insurance schemes, 2013

MOF: Ministry of Finance, MOL: Ministry of Labor, DH + HCs: district hospitals and health centers, RW: Relative Weight, DRG: Diagnostic Related Group

Table 2 Progressivity of health financing contribution, 2003–2006


Financing	2002		2004		2006	
sources	CI ^a	Fraction ^b	CI ^a	Fraction ^b	CI ^a	Fraction ^b
1. Direct tax	0.8221	0.20	0.8162	0.21	0.7687	0.23
2. Indirect tax	0.5594	0.38	0.5958	0.37	0.5512	0.33
3. Social insurance contribution	0.4975	0.06	0.4561	0.07	0.4492	0.08
4. Private insurance premium	0.3785	0.09	0.4221	0.09	0.4188	0.08
5. Direct payment	0.4883	0.27	0.4626	0.26	0.4705	0.28
Overall	0.5719	1.00	0.5822	1.00	0.5593	1.00

^aConcentration index (CI) > 0 indicates concentration among the economically better off. This means 'progressive' taxation, where the rich pay relatively more than the poor.

^bFraction of total health expenditure from National Health Accounts. *Source:* Prakongsai *et al.* (2009). of equitable access by all, dialysis solution was delivered to health centres, for patient home dialysis result in minimum travelling cost. A full account of discussion on the outcomes of the peritoneal dialysis-first policy was reported (Tantivess *et al.* 2013). Table 3 lists disease conditions that were singled out from closed end payment and paid on an agreed fee schedule. Number of cases and unit costs were used to estimate total budget requirement and approval in a transparent way.

Managing contracts: provider network as a gate keeper

When OP services were paid on a capitation basis, beneficiaries were required to register with a preferred provider network; typically, a DHS in their domicile district. When the beneficiary database was fully computerized a few years later, beneficiaries were allowed, four times a year, to register with another provider network they preferred especially among seasonal migrant workers such as taxi drivers and factory workers. Regular updates of electronic registries (birth, deaths, transfer across schemes and re-registrations) to all provider networks nationwide facilitate effective payment of capitation by NHSO.



Incidence of catastrophic health spending by wealth quintiles, >10% household consumption, 1996-2009

Figure 2 Incidence of catastrophic health expenditure prior to universal coverage (1996–2000) and after universal coverage (2002–2009) national averages. *Note:* catastrophic health expenditure refers to household spending on health that exceeds 10% of total household consumption expenditure. *Source:* Computed by Limwattananon S using the national dataset of household socio-economic surveys conducted by the National Statistical Office. Source: Evans *et al.* (2012).

 Table 3
 Specific diseases management and earmarked budget for UCS,

 Fiscal year (FY) 2014
 Fiscal year (FY) 2014

Disease management items	Percentage of budget	Target (cases)	
1. Asthma	0.14	106 950	
2. Tuberculosis	0.19	51 180	
3. Leukaemia and lymphoma, new cases	0.12	1231	
4. Cataract, including cost of soft lens	0.75	119 425	
5. Laser treatment for diabetic retinopathy	0.03	15 026	
6. Kidney stone using extracorpor- eal shock wave therapy	0.32	38 900	
7. Palliative care for end stage patients	0.03	5961	
8. Transplant (liver, heart, corneal, bone marrow and stem cell)	0.06	150	
9. ARV	1.51	188 000	
10. RRT	3.48	35 429	
11. Secondary prevention for diabetes and hypertension	0.54	2 726 800	
Total budget, US\$ million	4960		

ARV: Antiretrovirals.

Source: NHSO budget approved for fiscal year 2014.

Patients were entitled to services provided by their registered provider networks, while the network received an annual budget based on the capitation rate for OP service multiplied by total number of registries. The registered network, as a gate keeper, was liable to pay for the OP they referred to outside network out of its OP capitation budget. Patients bypassing without a proper referral were liable to pay OP services in full. Primary healthcare gate keeping function resulted in systems efficiency as most OP services can be and actually were provided by health centres and district hospitals with lower medical cost, time and transport costs shouldered by patients. Better outcome was noted, especially for chronic non-communicable diseases needing continual care, medication and home visits offered to those who cannot travel, such as stroke and elderly.


As the provider network under the Ministry of Public Health (MOPH) jurisdiction did not gain a corporate status, the MOPH, having the corporate status by law, signed an annual contract with the NHSO, but capitation payment and disbursement of admission services based on Diagnostic Related Group (DRG) were directly paid to the providers, not via MOPH. This ensures mutual financial accountability between provider networks and NHSO.

Access to the IP services does not require registration. Clinically indicated cases were admitted by a district hospital or referred to provincial hospital when beyond its clinical capacities. Upon discharge, summaries of clinical data were electronically submitted to NHSO where a specific DRG group was assigned with an attached relative weight. The total annual IP global budget when divided by the total relative weights of the whole country admissions resulted in reimbursement rate per weight. This is the amount disbursed to respective hospitals. The relative weight was regularly calibrated every 4–5 years. Upon series of stakeholder consultations, new relative weight was estimated based on expected admission utilization rate and unit cost per admission at different level of hospitals.

Managing geographical monopoly and quality issues

It is not uncommon to find a DHS the sole provider in a district; a geographical monopoly of health services in the locality. It was not possible not to contract such a DHS even though it was not accredited by the Healthcare Accreditation Institute (HAI) as people had no choice; travelling to neighbouring DHS was expensive and inconvenient. In such case, a strict application of quality condition such as accreditation or re-accreditation status for entering to contractual agreement was not viable.

A financial incentive was offered by NHSO in 2007 by recognizing a stepwise quality improvement initiated by HAI in 2003. Step 1 means risk identification system was installed; step 2 means quality assurance and quality improvement were



Accreditation status, 2003-2012 (Aug 2012)

Figure 3 Hospital accreditation status 2003–2012 and quality incentives offered by NHSO in 2007

in place and step 3 means a full accreditation or re-accreditation status every 2 and 3 years for the first and second re-accreditation, respectively (HAI 2013). Accreditation status certifies a sustained system of risk management and quality improvement. It should be noted that HAI focuses on strengthening hospitals as learning organizations where the national hospital standards is established and hospitals are empowered, step by step, to identify risk and build in risk management and quality improvement in all dimensions such as administration, ancillary and clinical service managements in line with the national standards. Since the inception, the HAI deliberately decided not to accredit hospital outcome per se but concentrated on quality improvement processes. Hence, accreditation is certifying a well established and sustained quality improvement system. However, HAI will assess the trend of clinical outcome in the forthcoming years. The NHSO earmarked a budget of 0.76 Baht per capita (35.7 million Baht per annum in total) to boost the quality improvement, with an application of the maximum score of 5 for the accredited hospitals (step 3), score 2 for step 2 and score 1 for step 1 status. It is noted that the scores 1, 2 and 5 were developed by NHSO for its incentive scheme and are not an outcome of the HAI accreditation process. Accredited primary health care facilities received a grant of 30 Baht per capita multiplied by catchment population it served. Figure 3 showed rapid improvement from steps 1 to 2 after quality incentives were offered in 2007. Note that an increase in the proportion of hospitals in step 0 from 1% in 2011 to 14% in 2012 was the effect of hospitals with accreditation status expired after 3 years and had not yet re-accredited.

Managing provider payment and annual budget

Unlike SHI which paid for both OP and IP services to public and private contracting hospitals on a per capita basis, UCS decided to apply two distinct payment methods; OP was paid by capitation and later on age- and gender-adjusted and IP was paid by a national global budget (later global budget at regional level) and within this budget envelope, using DRG relative weights for total national discharges to calculate reimbursement rate per weight to respective hospitals. The capitation fee for OP was estimated by multiplying utilization rate (visits per capita per year projected from historical data to that fiscal year) with the unit cost of providing OP services by different levels of care. Capitation fee for prevention and health promotion was estimated based on cost and quantity of age and gender-specific services to be provided such as ante natal care (ANC), family planning and cervical screening.

CSMBS applied fee for service for OP, but Comptroller General Department had limited capacity to regulate price and quantity of service provided. It directly disbursed healthcare providers (not patients), while no copayment was enforced. The excessive use of medicines outside the National List of Essential Medicines and diagnostics resulted in rapid cost escalation. In 2007, CSMBS replaced fee for services by DRG but no global budget for IP payment. DRG-based payment despite no global budget can contain costs well in 2008–2010, see Figure 4.

The UCS capitation payment sent a strong cost-containment signal, as financial risk was transferred from NHSO to providers. Capitation resulted in the use of generic essential medicines where cost was lower than branded and nonessential items. Providers need to keep a positive balance out of their capitation revenue; there was less incentives to prescribe more than necessary. Global budget and DRG for IP also contained cost effectively, preventing financial implications from possible DRG creep.

NHSO negotiated with Bureau of Budget, based on per capita budget multiplied by total number of the UCS beneficiaries. Different components of the per capita budget were estimated, based on utilization rate and unit cost of service. Administrative cost of NHSO was based on personnel, operating and capital cost. Budgets for OP and for prevention and health promotion were fully allocated to the contracting provider networks based on the number of registered population. The provider networks were allowed to keep the positive balance and shouldered the negative balance if any. Other high-cost services, such as RRT and Antiretroviral treatment, were managed separately.

Preventing the downside of close end payment

One major risk associated with closed end payment was underservice provision (Preker *et al.* 2013). Effective counter measures




Figure 4 CSMBS expenditure in total and on OP and IPs and annual growth, 1988-2010

introduced by NHSO included complaint management through 24-h call centre. The UCS members dialled 1330 to seek advice or make complaint where simple conflict resolution was settled between patients and providers by call centre staff. In 2012, there were 617694 calls of which 4370 (1%) were complaints, the remaining majority (93%) were counselling and advice to beneficiaries, 6% were queries by healthcare providers. Of the total 4370 complaints, 17% were poor quality and standard, 23% were poor service attention, 27% were being charged and 33% were not receiving services covered in the benefit package. In 2011, the complaint rate was low, 2.9 per 100000 patients (4386 out of the total 153 million combined OP visits and admissions). Of these total complaints, 97% were investigated and settled within 30 days as required by Law. Of the total settled cases, 54% found provider guilty where appropriate actions were taken, whereas 46% were misunderstood by beneficiaries.

Some interventions were not adequately accessed, e.g. cataract lens replacement due to supply side constraints. Backlogs of cataract blindness in the long waiting list was removed by taking the surgical procedure out of the IP DRG system and paying by a fixed fee schedule per case to hospitals and offering surgical fees to surgeons. Central bargaining by NHSO had brought down prices of soft lens significantly; hospitals can choose to reimburse on an agreed rate or to use lens supplied by the NHSO-negotiated vendors. Private hospitals with spare capacity were contracted with the same conditions applied to public hospitals. After the 2008 launch, numbers of cataract operation doubled in 4 years, from 71 823 lens replaced in 2008 to 143 553 in 2012, see Figure 5.

Executing monopsonistic purchasing power

NHSO exercised the monopsonistic power, as a single purchaser, to negotiate with suppliers of medicines and supplies over price given an assured quality. A committee consisting of NHSO officers and technical experts processed the open bidding and direct negotiation with oligopoly and monopoly suppliers. The priority items were those with high costs and/or high volumes. Table 4 summarizes total saving from exercising monopsonistic power, up to US\$ 188 million in recent few years.

Discussion

Not only the purchasing functions contribute to achievement of UHC goals, but also enabling factors worth mentioning. First, the extensive geographical coverage of health delivery systems, DHS plays a strategic hub for provisions of primary and secondary health services and translates policy intentions into equity outcomes (Prakongsai et al. 2009). Second, the effective referral backup to tertiary care and excellent centres in the Region, ensured access to specialist care. It is noted that referral is required for OP as the DHS contractor network receiving capitation budget is the funding holder and is responsible to pay for the referred OPs. IPs paid by DRG in a global budget ceiling does not required referral. Referral statistics were kept at local level for financial management purposes and was not transmitted to NHSO. Third, an extensive road and availability of public transport nationwide facilitated physical access. Others are, for example, level of female literacy and trust in MOPH health services where health professional were qualified and observed work etiquette.




Figure 5 Number of cataract surgery before and after unbundling from DRG and replace by special payment. Source: NHSO (2012).

Table 4	Cost saving fro	m central negotiation	for medical supplies and	l medicines, various years, US \$

	Market unit price	Negotiated price	Units purchased	Cost difference	Cost savings
Medical supplies					
Folding lens (2011–2012)	133	93	64 100	40	2 564 000
Unfolding lens (2011–2012)	133	23	7197	110	791 670
Balloon stent (2009–2012)	667	333	26 655	334	8 902 770
Coronary stent (2009–2012)	1000	167	10 575	833	8 808 975
Drug-coated stent (2009–2012)	2833	567	33 794	2266	76 577 204
DES alloy stent (2012)	1833	833	343	1000	343 000
Medicines					
ARV (2010–2012)	747	658	29 973	89	2 667 597
High cost drug (2010–2012)	4508	3197	4674	1311	6127614
Influenza vaccine (2010–2012)	7	5	643 319	2	1 286 638
Erythropoietin (2009–2012)	22	8	1 634 239	14	22 879 346
CAPD solution (2010-2012)	7	4	19 095 657	3	57 286 971
Total cost saving to UCS					188 235 785

DES: Drug eluting stent, CAPD: Continuous ambulatory peritoneal dialysis. *Source*: NHSO 2012.

Unavoidably, developing country will face geographical monopoly, which hampers competitive contract model. Other mechanisms such as hospital accreditation, quality improvement and quality incentives are comprehensive intervention to gradually overcome unsatisfactory quality of care.

Provider payment is the most critical factor contributing to financial risk protection and technical efficiency. A few lowand middle-income countries where closed-end payment was not widely applied, fee for services result in cost escalation such as in China (Hu *et al.* 2008; Yip *et al.* 2010) and high level of out-of-pocket payment from balance billing by members of PhilHealth in the Philippines. Most countries in the region are moving towards capitation and DRG, such as Vietnam, Philippines and China. NHSO has a very small administrative budget: first it has no mandate to collect premium from members, as UCS is financed by general taxation. Second, it did not have a large staff body to review itemized fee for service claims, as DRG and Global Budget was applied for IP and capitation for OP payments. NHSO administrative cost was 1.06% of total annual UCS budget over the last 11 years between 2002 and 2012.

Conclusion and policy lessons

Strategic purchasing supports achievement of UHC goals. Contracting OP services to DHS results in

equitable access to care, where referral backup is essential. Geographical monopoly limits competitive contracting, for which issues on quality of care are addressed by hospital accreditation and other quality incentive mechanisms. DHS as gate keeping contributes to rational use of services and systems efficiency.

Comprehensive benefit package offered free at point of service contributes to financial risk protection. Comprehensive package is financially feasible as the self-cost-contained closed end payment was applied. In contrast, CSMBS fee for service OP services results in excessive use of health resources and cost escalations. Potential drawbacks of closed end payment especially under-provision and poor quality are addressed by complaint handling via 24-h call centre, unbundling services from capitation such as chemotherapy, radiation therapy and antiretroviral therapy (ART), and from DRG such as cataract and pay on an agreed few schedules. DRG creep is countered by medical audits and NHSO reclaims of the over-disbursed amounts, see Box 1. Global budget prevents financial impacts from DRG creep. NHSO institutional capacities, especially executing monopsonistic purchasing was gradually initiated, whereas external partners contribute to HTA evidence guiding policy decision on inclusion of new medicines and interventions into benefit package.

Box 1

Medical Audit in action, 8 years NHSO experiences. It was not until 2006 that NHSO settled medical audit of IP claims when the number of trained independent physicians and coding auditors became adequate. Initially, random audit of 1% of medical records in all hospitals was applied between 2006 and 2008: later selective audits of potential errors using screening criteria were applied since 2009. Three errors were identified using auditors as gold standard; (1) between attending physician and medical auditor discharge summary, called 'summary error'; (2) between hospital and auditor coders using hospital discharge summary, called 'coding error' and (3) relative weight computed from hospital claim and auditor, called 'changes in relative weight', which can be over- or under-claimed by hospitals, for which reclaiming from and additional pay to hospitals by NHSO. Appeal provision was made available if hospitals do not agree with verification by auditors. Medical audit facilitates NHSO mutual accountability: in 2012. NHSO audited 1.2% of total IP claims and reclaimed the over-reimbursement by hospitals the total amount of US\$ 6.07 million.

Acknowledgements

We appreciate contributions by senior management and staffs in the NHSO.

Funding

This study was financially supported by WHO-South East Asia Regional Office. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest statement: None declared.

References

- Evans TG, Chowdhury MR, Evans DB et al. 2012. Thailand's Universal Coverage Scheme: Achievements and Challenges. An Independent Assessment of the First 10 Years (2001–2010). Nonthaburi: Health Insurance System Research Office.
- HAI. Healthcare Accreditation Institute, Thailand. http://www.ha.or.th/ haweb/index.php/home-2, accessed 3 September 2013.
- HITAP. Health Intervention and Technology Assessment Program Profiles. http://www.hitap.net/en/about/background, accessed 3 September 2013.
- Hu S, Tang S, Liu Y *et al.* 2008. Reform of how health care is paid for in China: challenges and opportunities. *Lancet* **372**: 1846–53.
- Jongudomsuk P, Limwattananon S, Prakongsai P et al. 2012. Evidencebased health financing reform in Thailand (chapter 16). In: Clements B, Coady D, Gupta S (eds). The Economics of Public Health Care Reform in Advanced and Emerging Economies. Washington: International Monetary Fund, pp. 307–26.
- Kasemsup V, Prakongsai P, Tangcharoensathien V. 2006. Budget impact analysis of a policy on universal access to RRT under universal coverage in Thailand. *Journal of the Nephrology Society of Thailand* 12(suppl 2):136–48.
- Limwattananon S, Neelsen S, O'Donnell O et al. 2013. Universal coverage on a budget: impacts on health care utilization and outof-pocket expenditures in Thailand. Tinbergen Institute Discussion Paper, TI 2013-067/V. Tinbergen Institute.
- Limwattananon S, Tangcharoensathien V, Prakongsai P. 2007. Catastrophic and poverty impacts of health payments: results from national household surveys in Thailand. Bulletin of the World Health Organization 85: 600–6.
- Limwattananon S, Tangcharoensathien V, Tisayathicom K, Boonyapaisarncharoen T, Prakongsai P. 2012. Why has the universal coverage scheme in Thailand achieved a pro-poor public subsidy for health care? *BMC Public Health* **12**(suppl 1): S6.
- O'Donnell O, van Doorslaer E, Rannan-Eliya RP *et al.* 2007. The incidence of public spending on healthcare: comparative evidence from Asia. *The World Bank Economic Review* **21**: 93–123.
- Preker A, Lindner M, Chernichovsky D, Schellekens O (eds). 2013. Scaling Up Affordable Health Insurance: Staying the Course. Washington: the World Bank.
- Prakongsai P. 2008. The impact of the universal coverage policy on equity of the Thai Health Care System. *Ph.D. Thesis*. London School of Hygiene and Tropical Medicine, University of London.
- Prakongsai P, Limwattananon S, Tangcharoensathien V. 2009. The equity impact of the universal coverage policy: lessons from Thailand. *Advances in Health Economics and Health Services Research* **21**: 57–81.
- Prakongsai P, Palmer N, Uay-Trakul P, Tangcharoensathien V, Mills A. 2007. What Happened to Poorer Thai Households When Renal Replacement Therapy Was Excluded from the National Benefit Package? Nonthaburi: International Health Policy Program.
- Prakongsai P, Tangcharoensathien V, Kasemsup V et al. 2006. Policy recommendation on universal access to renal replacement therapy under universal coverage in Thailand. Journal of the Nephrology Society of Thailand **12**(suppl 2): 37–49.
- Tangcharoensathien V, Kamolratanakul P. 2008. Making sensible rationing: the use of economic evidence and the need for

methodological standards. *Journal of the Medical Association of Thailand* **91**: S4–7.

- Tangcharoensathien V, Kasemsup V, Teerawattananon Y et al. 2005. Universal Access to Renal Replacement Therapy in Thailand: A Policy Analysis. Nonthaburi: International Health Policy Program & Nephrology Society of Thailand.
- Tangcharoensathien V, Pitayarangsarit S, Patcharanarumol W *et al.* 2013. Promoting universal financial protection: how the Thai universal coverage scheme was designed to ensure equity. *Health Research Policy and Systems* **11**: 25.
- Tangcharoensathien V, Prakongsai P, Limwattananon S, Patcharanarumol W, Jongudomsuk P. 2009. From targeting to universality: lessons from the health system in Thailand. In: Townsend P (ed). Building Decent Societies: Rethinking the Role of Social Security in Development. Hampshire: Palgrave Macmillan, pp. 310–22.
- Tangcharoensathien V, Vasavid C, Kasemsup V. 2006. An opinion poll on universal access to RRT under UC in Thailand. *Journal of the Nephrology Society of Thailand* 12(suppl 2): 21–36.

- Tantivess S, Teerawattananon Y, Mills A. 2009. Strengthening costeffectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program. *Pharmacoeconomics* **27**: 931–45.
- Tantivess S, Werayingyong P, Chuengsaman P, Teerawattananon Y. 2013. Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. *BMJ* 346: f462.
- Teerawattananon Y, Mugford M, Tangcharoensathien V. 2007. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. *Value Health* **10**: 61–72.
- Yip W, Hsiao W, Meng Q, Chen W, Sun X. 2010. Realignment of incentives for health-care providers in China. *Lancet* **375**: 1120–30.
- Yothasamut J, Putchong C, Sirisamutr T, Teerawattananon Y, Tantivess S. 2010. Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. *BMC Health Services Research* **10**(suppl 1): S5.